Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria ChemopreventionArticle Published on 2023-04-182024-08-28 Journal: Med Instrum [Category] 말라리아, [키워드] drug-drug interaction efavirenz malaria Pregnancy Ultrafiltration unbound piperaquine.
Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery코비드-19와 인공 지능: 게놈 시퀀싱, 약물 개발 및 백신 발견Review Published on 2022-02-012022-09-11 Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] abacavir agility Almitrine applied approval article artificial artificial intelligence Atazanavir bioinformatics Care challenges clinical trial clinical trials collecting data COVID-19 COVID-19 pandemic COVID-19 virus databases deep learning difficulty dolutegravir drug Drug development Drug repurposing drugs efavirenz Genome sequencing genomic genomic sequence genomic sequencing Google Google Scholar growth Health Health care help hydrochloride inhibitor internal and external interpretability machine learning Messenger RNA mesylate Olaparib omicron PARP1 provide recognize Remdesivir Ritonavir Roflumilast SARS- CoV-2 SARS-CoV-2 proteome sequence Sequencing strain structural proteins therapeutic agent therapeutic effect Vaccine Vaccines variants variants of concern Viral vector vaccines VoC was done [DOI] 10.1016/j.jiph.2022.01.011 PMC 바로가기 [Article Type] Review
Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 proteinArticle Published on 2022-02-012023-07-07 Journal: Journal of biochemical and molecular toxicology [Category] COVID19(2023년), [키워드] 2019-nCoV ACE2 efavirenz zidovudine [DOI] 10.1002/jbt.22948 PMC 바로가기
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and EfavirenzCYP2B6 Dolutegravir와 Efavirenz의 유전자형 및 체중 증가 차이Online Only Articles Published on 2021-12-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] All participants Antiretroviral therapy ARMS ART baseline baseline CD4 baseline characteristics changes in Characteristics concentrations CYP2B6 difference dolutegravir dual-energy x-ray absorptiometry DXA efavirenz emtricitabine explain fat fumarate Gain Genotype genotyping greater HIV-1 Human immunodeficiency virus impair impaired weight men participant PLWH polymorphism Randomized Result RNA tenofovir tenofovir disoproxil fumarate variable weight weight gain women [DOI] 10.1093/cid/ciaa1073 PMC 바로가기 [Article Type] Online Only Articles
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1태반 및 모유 전달을 통한 Dolutegravir에 유아 노출 : Dolphin-1의 인구 약동학 분석Online Only Articles Published on 2021-09-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 1:1 Breast breast milk breastmilk contributed CORD covariate covariates Coverage described diagnosed dolutegravir efavirenz Effect elimination rate evaluate exposure to fetal gestation HIV Human immunodeficiency virus immunodeficiency virus Infant infant pharmacokinetics inhibitory concentration investigated Maternal maternal plasma median median time milk mixed-effects modeling participant pharmacokinetic plasma plasma sample Population Population pharmacokinetics predicted Pregnancy presenting Prevent profiles Prophylactic Prophylaxis provided Randomized Rapid reduction in Result South Africa switch therapy threshold Transmission treatment initiation Uganda umbilical Umbilical cord waned was used women [DOI] 10.1093/cid/ciaa1861 PMC 바로가기 [Article Type] Online Only Articles
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial인간 면역 결핍 바이러스 유형 1 감염을 가진 치료-상대 성인의 도라비린/라미부딘/텐 노포 비르 디오 록시 푸마 레이트 (TDF) 대 efavirenz/emtricitabine/tdf : 무작위, 이중 앨범, 상 3 단계 비 제 3 단계 비정기 시험의 96 주 결과.Major Articles and Commentaries Published on 2021-07-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 95% confidence interval adverse event analyses antiretroviral ARMS baseline change cholesterol clinical demonstrated doravirine double-blind drug efavirenz Efficacy efficacy end point emtricitabine end point event food fumarate HDL-C HIV-1 Human Human immunodeficiency virus human immunodeficiency virus type 1 Infection inhibitor lamivudine less Lipid lipids lipoprotein cholesterol Low-density lipoprotein Low-Density Lipoprotein cholesterol margin multicenter Neuropsychiatric NNRTI participant Participants phase Phase 3 point of interest profile proportion Randomized Rash Registration Result Safety study drug Support Tablet tenofovir tenofovir disoproxil tenofovir disoproxil fumarate the mean Tolerability Total cholesterol Treatment treatment difference treatment-naive Trial Type Week [DOI] 10.1093/cid/ciaa822 PMC 바로가기 [Article Type] Major Articles and Commentaries
Computational drug discovery and repurposing for the treatment of COVID-19: A systematic reviewCOVID-19 치료를 위한 컴퓨터 약물 발견 및 용도 변경: 체계적인 검토Article Published on 2021-01-012022-08-31 Journal: Bioorganic chemistry [Category] SARS, 신약개발, 유전자 메커니즘, 치료법, 치료제, [키워드] AIDS Analysis Anticoagulant anticoagulant drug antiviral drug antiviral drugs applied approved approved drug approved drugs article asunaprevir Atazanavir AutoDock AutoDock vina best boceprevir Chloroquine clinical evidence clinical study Clocortolone CMV Computational drug computational method Computational methods COVID-19 COVID-19 progression COVID-19 therapy COVID-2019 crystal structure Dabigatran darunavir database disease disease outbreak docking tool dolutegravir drug Drug discovery Drug repurposing drugs Ebola efavirenz Efficacy eligible English entecavir FIVE formoterol Future Ganciclovir Grazoprevir HBV HCV Indinavir inhibit itraconazole life-threatening list Lomibuvir Lopinavir majority matter mechanism molecular mycophenolic acid nelfinavir non-structural protein non-structural proteins Novel coronavirus occurred offer outbreak Papain Papain-like protease Penciclovir protease provide raltegravir Remdesivir Repurposed drug Repurposed drugs ribavirin Ritonavir RNA-dependent RNA polymerase saquinavir SARS-CoV-2 SARS-CoV2 sequence Simeprevir systematic review telaprevir the disease therapeutic therapy treat Treatment treatment of COVID-19 [DOI] 10.1016/j.bioorg.2020.104490 PMC 바로가기 [Article Type] Article
Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustmentarticle Published on 2020-12-312024-09-01 Journal: Malawi Med J [Category] 말라리아, [키워드] Ataxia efavirenz HIV malaria Malawi neurotoxicity post-malaria neurologic syndrome [Article Type] article
Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenzArticle Published on 2020-08-112022-10-31 Journal: Heliyon [Category] COVID-19, [키워드] acute respiratory syndrome approved calculated Compound compounds coronavirus COVID-19 COVID-19 disease COVID-19 infection docking drug-likeness efavirenz FDA FDA approved drug FIVE functional highest HIS163 His41 HIV inhibitor interacting residue Interaction lowest molecular Molecular docking study NNRTI performed pharmaceutical Pharmaceutical chemistry Phe140 podophyllotoxin protease protease inhibitors SARS-CoV-2 selected Theoretical chemistry transcriptase treat Virtual screening virus worldwide pandemic [DOI] 10.1016/j.heliyon.2020.e04642 PMC 바로가기 [Article Type] Article
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialHIV 감염, 항레트로바이러스 경험이 없는 성인에서 표준 용량 대비 저용량 테노포비르 디소프록실 푸마르산염 및 에파비렌즈의 효능 및 안전성: 다기관, 무작위, 비열등성 시험Article Published on 2020-05-042022-09-06 Journal: Emerging Microbes & Infections [Category] Communicable Disease, [키워드] 95% CI adverse event adverse events antiretroviral ARV assigned change comparable dose drug efavirenz Efficacy evaluate filtration rate fumarate glomerular filtration rate HIV HIV-1 HIV-1 infection infected patients initial intention-to-treat analysis lamivudine low dose lower dose lower toxicity multicentre non-inferiority non-inferiority margin non-inferiority trial occurred Open-label participant primary endpoint proportion Randomized Randomly receive receiving reduced regimen safety profile Standard dose Support tenofovir tenofovir disoproxil tenofovir disoproxil fumarate therapy Toxicity Treatment treatment difference Trial two groups [DOI] 10.1080/22221751.2020.1752609 PMC 바로가기 [Article Type] Article